Arcutis Biotherapeutics Interest Expense 2011-2026 | ARQT

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Arcutis Biotherapeutics

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
443 K	47 K	-731 K	5.82 M	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
5.82 M	-731 K	1.4 M

Quarterly Interest Expense Arcutis Biotherapeutics

2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
2.1 M	2.73 M	-	4.18 M	5.23 M	4.04 M	-	2.72 M	3.12 M	7.04 M	-	4.9 M	2 M	1.84 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
7.04 M	1.84 M	3.63 M

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Allakos ALLK	8 K	-	-	$ 28.6 M	USA
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA
Alterity Therapeutics Limited ATHE	2.28 K	$ 4.57	-0.22 %	$ 11 B	Australia
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA
AlloVir ALVR	1.44 M	-	4.14 %	$ 49.1 M	USA
Compugen Ltd. CGEN	281 K	$ 2.65	-2.93 %	$ 248 M	Israel
I-Mab IMAB	722 K	-	-	$ 866 M	China
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
Ampio Pharmaceuticals AMPE	-5.01 K	-	-11.43 %	$ 502 K	USA
Genfit SA GNFT	4.68 M	-	2.54 %	$ 160 B	France
ACADIA Pharmaceuticals ACAD	1.82 M	$ 22.5	-0.75 %	$ 3.73 B	USA
Applied Molecular Transport AMTI	-4 K	-	-	$ 10.1 M	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Applied Therapeutics APLT	-27 K	-	-	$ 8.42 M	USA
Aptinyx APTX	737 K	-	-39.0 %	$ 4.57 M	USA
Galapagos NV GLPG	1.03 M	$ 27.55	-3.08 %	$ 2.69 B	Belgium
Avenue Therapeutics ATXI	294 K	-	-52.27 %	$ 4.45 M	USA
AgeX Therapeutics AGE	51 K	-	-10.17 %	$ 12.2 K	USA
Aravive ARAV	2.84 M	-	-13.39 %	$ 1.45 M	USA
Atreca BCEL	3 K	-	-11.76 %	$ 5.79 M	USA
BioNTech SE BNTX	14.2 M	$ 100.4	-1.63 %	$ 27.2 B	Germany
Brainstorm Cell Therapeutics BCLI	-93 K	-	-2.5 %	$ 5.88 M	USA
BioDelivery Sciences International BDSI	-6 K	-	-4.8 %	$ 255 M	USA
Innoviva INVA	16.7 M	$ 23.23	-1.94 %	$ 1.57 B	USA
Innate Pharma S.A. IPHA	440 K	$ 1.45	3.57 %	$ 235 M	France
Aquestive Therapeutics AQST	6.55 M	$ 4.07	-0.61 %	$ 435 M	USA
Inventiva S.A. IVA	12.2 M	$ 4.96	-1.1 %	$ 138 M	France
Jaguar Health JAGX	67 K	$ 0.23	-5.27 %	$ 536 K	USA
KalVista Pharmaceuticals KALV	8.56 M	$ 26.71	38.8 %	$ 1.44 B	Britain
Autolus Therapeutics plc AUTL	36.7 M	$ 1.4	-5.74 %	$ 373 M	Britain
Can-Fite BioPharma Ltd. CANF	227 K	$ 2.88	-1.03 %	$ 4.74 M	Israel
BeiGene, Ltd. BGNE	-42.6 M	-	0.49 %	$ 251 B	Cayman-islands
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA